title: Recurrent idiopathic neuroretinitis: natural history and effect of treatment.
abstract: BACKGROUND
  Previous reports have emphasized the self-limited nature of idiopathic neuroretinitis. There is less information about a subgroup of patients who suffer recurrent episodes with worse visual outcome. We sought to better characterize the clinical features of recurrent idiopathic neuroretinitis including the effects of immunosuppressive treatment.
  
  
  METHODS
  Retrospective chart review of neuroretinitis patients from a single institution from 1983 to 2008. Inclusion criteria included two or more episodes of acute visual loss with disc oedema and macular exudates in a star pattern. Cases due to a specific infectious or inflammatory aetiology were excluded.
  
  
  RESULTS
  Forty-one patients were included with an average follow up of 67 months. Median age at the time of the first episode was 28 years (range 10-54 years). Attacks were bilateral sequential in 34 patients (83%). We documented a total of 147 episodes in 75 eyes with an average of 3.6 attacks per patient. The average interval between attacks was 3 years. Visual field loss had a nerve fibre bundle pattern in most cases. Only 36% of eyes retained 6/12 or better visual acuity and greater than two-thirds of their visual field. Long-term immunosuppressive treatment in 13 patients decreased the attack rate by 72%.
  
  
  CONCLUSIONS
  Recurrent idiopathic neuroretinitis typically affects young adults, with no gender preference. Recovery is limited and visual loss is cumulative with repeated attacks, often resulting in severe permanent visual loss. Immunosuppressive treatment appears to lessen the attack frequency.
authors: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.
authors: Seema V
authors: SV
authors: Sundaram
authors: Valerie A
authors: VA
authors: Purvin
authors: Aki
authors: A
authors: Kawasaki
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009902:Optic Neuritis / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D014792:Visual Acuity / Q000502:physiology; D058609:Visual Field Tests; D014794:Visual Fields
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents